CMC Biologics and IDT Biologika expand ADC manufacturing collaboration

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/Choreograph)
(Image: iStock/Choreograph)

Related tags Monoclonal antibodies

CMC Biologics and IDT Biologika have added Cerbios-Pharma SA and Oncotec Pharma Produktion GmbH to the companies’ PROVEO Partnership – a strategic collaboration for manufacturing antibody drug conjugates (ADCs).

According to the companies, with its new members the partnership will now be able to support the development and manufacture of complex ADCs from drug substance to final drug product.

PROVEO also offers project management, supply chain system, and quality systems.

As part of the partnership, CMC Biologics provides monoclonal antibody production and IDT Biologika performs analytical services, supply chain and secondary packaging through to final drug product.

Moving forward, Cerbios will carry out process development, manufacture of the cytotoxic drug-linker payload, in addition to providing conjugation services of the ADC drug substance. Oncotec will provide aseptic fill and lyophilization of the ADC drug product.

The services will be available through the PROVEO Partnership in early 2017.

Related news

Show more

Related products

show more

Difco TC Yeastolate UF in scale-up optimization

Difco TC Yeastolate UF in scale-up optimization

Content provided by Thermo Fisher Scientific Gibco Culture for Bioprocessing | 16-Oct-2023 | White Paper

Review the impact of—not only adding peptones as a supplement to your cell culture—but also the importance of concentration and timing as a feed strategy...

Related suppliers